Skip to Main Content

A version of this story also appeared in STAT’s daily biotech newsletter, The Readout. Subscribe here.

Biotech venture capitalists and their portfolio companies had a historic first quarter — but that doesn’t mean the industry is out of the woods just yet.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!